Clinical Trial Update: Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003 [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating anlotinib plus penpulimab (AK105) for chemo-refractory metastatic colorectal cancer (ALTER-C003).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Penpulimab

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Colorectal Cancer | Phase 2 | Status: UNKNOWN